Welcome to Campus Sanofi Malaysia

Join us for an insightful RSV Prevention event featuring expert presentations on the latest advances in respiratory syncytial virus prevention strategies for all infants. Gain valuable insights through four comprehensive video presentations, into systematic reviews of effectiveness data, healthcare system implementation approaches, global prevention strategies, and the significant impact of RSV prevention on reducing disease burden in pediatric populations.​

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.

LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.

Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.